Advancements were made in the understanding of the human immunodeficiency virus (HIV) and the management of patients with the acquired immunodeficiency syndrome (AIDS) in many parts of the United States after such patients were first identified in 1981. Nevertheless, the relatively small city of San Francisco contributed a disproportionate share of them, due largely to the city's inclusive political and community response to the HIV/AIDS epidemic, including the activities of its Department of Public Health and San Francisco General Hospital (SFGH). San Francisco's colorful history, multicultural character, and tradition of tolerance attracted many patients who would develop HIV/AIDS to the city. The same factors underlaid the community's compassionate response when large numbers of these patients needed medical services. These factors also motivated the physicians, nurses, and other health professionals at SFGH who cared for the patients on the world's first inpatient AIDS ward.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1513/AnnalsATS.201208-039PS | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Innate immune memory in chronic HIV and HIV-associated neurocognitive disorders (HAND): potential mechanisms and clinical implications.
J Neurovirol
December 2024
Department of Pharmacology and Physiology, Drexel University College of Medicine, Philadelphia, PA, 19102, USA.
Although antiretroviral therapy (ART) has dramatically improved the outlook of the HIV/AIDS pandemic, people living with HIV (PLWH) on suppressive therapy are still at higher risk for a range of comorbidities including cardiovascular disease (CVD) and HIV-associated neurocognitive disorders (HAND), among others. Chronic inflammation and immune activation are thought to be an underlying cause of these comorbidities. Many of the factors thought to drive chronic inflammation and immune activation in HIV overlap with factors known to induce trained immunity.
View Article and Find Full Text PDFSLAMF7 defines subsets of human effector CD8 T cells.
Sci Rep
December 2024
Singapore Immunology Network (SIgN), Agency for Science Technology and Research (A*STAR), Immunos Building, 8A Biomedical Grove, Biopolis, Republic of Singapore.
Long-term control of viral replication relies on the efficient differentiation of memory T cells into effector T cells during secondary immune responses. Recent findings have identified T cell precursors for both memory and exhausted T cells, suggesting the existence of progenitor-like effector T cells. These cells can persist without antigenic challenge but expand and acquire effector functions upon recall immune responses.
View Article and Find Full Text PDFCharacterization of serological responses to Plasmodium falciparum (Pf) is of interest to understand disease burden and transmission dynamics; however, their interpretation is challenging. Dried blood spots from 30,815 participants aged 6 months to 15 years from the 2018 Nigeria HIV/AIDS Indicator and Impact Survey were analyzed by multiplex bead-based assay to measure immunoglobulin G (IgG) to Pf-stage-specific MSP-1, AMA-1, GLURPR0, LSA-1, and CSP. These IgG levels were analyzed by principal component analysis (PCA).
View Article and Find Full Text PDFDiagnosis and Management of Kaposi Sarcoma-Associated Herpesvirus Inflammatory Cytokine Syndrome in Resource-Constrained Settings: A Case Report and an Adapted Case Definition.
Trop Med Infect Dis
December 2024
Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Kaposi sarcoma-associated herpes virus (KSHV), also known as human herpes virus 8 (HHV-8), is the primary etiologic cause of Kaposi sarcoma (KS) and KSHV Inflammatory Cytokine Syndrome (KICS). Patients with KICS demonstrate symptoms of systemic inflammation, high KSHV viral load, elevation of inflammatory markers, and increased mortality. Management requires rapid diagnosis, treatment of underlying HIV, direct treatment of KS, and addressing the hyperimmune response.
View Article and Find Full Text PDFD-peptide hydrogels as a long-acting multipurpose drug delivery platform for combined contraception and HIV prevention.
J Control Release
December 2024
School of Pharmacy, Queen's University Belfast, Medical Biology Centre, 97 Lisburn Road, Belfast, Northern Ireland BT9 7BL, United Kingdom. Electronic address:
Article Synopsis
- New multipurpose prevention technologies for women prioritize reducing HIV risks and preventing unwanted pregnancies, promoting greater sexual health choices.
- A novel long-acting injectable platform combines the HIV drug MIV-150 and the contraceptive etonogestrel using a specially designed D-peptide that forms a drug-releasing hydrogel after injection.
- The technology shows promising biostability, low toxicity, and sustained delivery of both drugs in animal models for nearly 50 days, indicating its potential for effective long-term use.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!